Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 151 #1
TickerTLOG [NASD]
CompanyTetraLogic Pharmaceuticals Corporation
CountryUSA
IndustryBiotechnology
Market Cap55.99MEPS (ttm)-1.61
P/E-EPS this Y-59.40%
Forward P/E-EPS next Y39.20%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B1.60EPS Q/Q-65.60%
Dividend-Sales Q/Q-
Insider Own3.70%Inst Own43.00%
Insider Trans14.91%Inst Trans-0.36%
Short Float1.03%EarningsMay 28
Analyst Recom2.00Target Price9.50
Avg Volume95.30K52W Range3.51 - 6.49
May-06-15 02:24PMTetraLogic Announces Termination of Public Offering at noodls
May-06-15 12:52PMTetraLogic Announces Termination of Public Offering GlobeNewswire
May-06-15 12:04PMPDF Add to Briefcase File is in Briefcase at noodls
May-06-15 12:04PMTetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial at noodls
May-06-15 11:15AMMalvern biopharm company's stock plunges after study is stopped at bizjournals.com
May-06-15 10:14AMTetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial GlobeNewswire
May-06-15 10:06AM10:06 am TetraLogic Pharmaceuticals trading halted, news pending
May-01-15 01:33PMTETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
May-01-15 09:55AMPDF Add to Briefcase File is in Briefcase at noodls
May-01-15 09:55AMTetraLogic Announces Pricing of $25 Million Public Offering at noodls
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes. The company's pre-clinical programs also comprise Phase I/II open-label, non-randomized clinical trial of Birinapant administered with conatumumab in third-line ovarian cancer; and Phase I clinical trial of Birinapant in subject with chronic Hepatitis B virus. In addition, its clinical-stage product candidate, suberohydroxamic acid 4-methoxycarbonyl phenyl ester, is in Phase II clinical trial for the treatment of early-stage cutaneous T-cell lymphoma. The company has collaboration with Amgen, Inc. for exploring the combination of Birinapant administered with Amgen's TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyers Pete A.CFO & TreasurerMar 27Buy4.355,00021,750153,891Mar 31 07:03 AM
BUCHI J KEVINPresident & CEOJan 07Buy5.045,00025,181325,714Jan 09 07:00 AM
Begley Colin GlennChief Scientific Officer & SVPDec 10Buy6.165,90036,344198,134Dec 12 06:18 AM
BUCHI J KEVINPresident & CEODec 09Buy6.015,00030,060320,714Dec 11 07:38 AM
Meyers Pete A.CFO & TreasurerDec 04Buy4.941,0345,108148,891Dec 08 07:29 AM
TickerANAD [NASD]
CompanyAnadigics, Inc.
CountryUSA
IndustrySemiconductor - Integrated Circuits
Market Cap84.19MEPS (ttm)-0.45
P/E-EPS this Y32.80%
Forward P/E-EPS next Y83.30%
PEG-EPS past 5Y13.30%
P/S0.98EPS next 5Y20.00%
P/B1.96EPS Q/Q50.00%
Dividend-Sales Q/Q-42.40%
Insider Own5.40%Inst Own22.50%
Insider Trans0.00%Inst Trans1.07%
Short Float7.43%EarningsMay 05/a
Analyst Recom2.80Target Price1.50
Avg Volume426.69K52W Range0.55 - 1.55
May-06-15 12:10PMAnadigics (ANAD) Q1 Loss Meets Estimates, Narrows Y/Y - Analyst Blog
May-05-15 06:13PM7 Key After-Hours Movers on Tuesday at 24/7 Wall St.
May-05-15 05:14PMANADIGICS INC Files SEC form 8-K, Results of Operations and Financial Condition
May-05-15 04:51PMAnadigics reports 1Q loss AP
May-05-15 04:23PMANADIGICS ANNOUNCES FIRST QUARTER RESULTS at noodls
May-05-15 04:07PM4:07 pm Anadigics beats by $0.01, reports revs in-line
May-05-15 04:00PMANADIGICS Announces First Quarter Results GlobeNewswire
May-05-15 07:07AMQ1 2015 ANADIGICS Inc Earnings Release - After Market Close
Apr-24-15 04:53PMANADIGICS INC Files SEC form 8-K, Other Events
ANADIGICS, Inc. designs, manufactures, and sells radio frequency (RF) semiconductor solutions for infrastructure and mobile communications, and data transmission markets. The company's product portfolio includes line amplifiers, reverse path amplifiers, front-end integrated circuits (FEICs), and power amplifiers (PAs). Its CATV solutions consist of line amplifiers, reverse path amplifiers, and other RF products that provide the critical link within CATV infrastructure communications networks, as well as CPE devices, such as set-top boxes and cable modems. The company's Wi-Fi infrastructure products comprise PAs and FEICs, which enable wireless connectivity for infrastructure and multimedia applications, including access points, routers, media gateways, and set-top boxes. Its wireless infrastructure solutions consist of PAs that are crucial components in 3G and 4G small-cell base stations, such as picocells, enterprise-class femtocells, and CPE devices, which help carriers expand broadband network coverage and support data transmission. The company's Wi-Fi mobile products comprise FEICs and PAs that are designed to enable Wi-Fi connectivity in smartphones, tablets, notebooks, and gaming systems. Its cellular products include PAs, which enable 3G and 4G wireless connectivity in mobile handsets, smartphones, tablets, and notebooks. The company also provides foundry services, including manufacture and test of VCSEL devices for various sensing applications. It sells its products through direct sales, as well as through independent manufacturers' representatives and distributors. ANADIGICS, Inc. was founded in 1984 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher Terrence GVice President & CFODec 31Option Exercise0.665,0003,285312,574Jan 27 04:45 PM
Cresci David JPresidentDec 31Option Exercise0.665,0003,285560,847Jan 27 04:44 PM
Michels RonaldChairman & CEODec 31Option Exercise0.665,0003,2851,201,509Jan 27 04:42 PM
Fellows DavidDirectorNov 04Buy0.70100,00069,920295,611Nov 04 04:36 PM
Gallagher Terrence GVice President & CFOOct 30Buy0.6825,00016,925317,574Oct 31 08:36 AM
TickerARDX [NASD]
CompanyArdelyx, Inc.
CountryUSA
IndustryBiotechnology
Market Cap155.17MEPS (ttm)-0.18
P/E-EPS this Y18.40%
Forward P/E6.04EPS next Y-10.00%
PEG-EPS past 5Y0.00%
P/S4.91EPS next 5Y30.00%
P/B2.54EPS Q/Q55.30%
Dividend-Sales Q/Q-78.20%
Insider Own15.70%Inst Own75.80%
Insider Trans-14.95%Inst Trans-3.16%
Short Float1.79%EarningsFeb 25
Analyst Recom1.30Target Price28.75
Avg Volume84.46K52W Range10.40 - 35.48
May-05-15 06:13PMArdelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria at noodls
May-05-15 05:00PMVitae Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
May-05-15 04:06PM4:06 pm Ardelyx announces results from its Phase 2a clinical trial evaluating Tenapanor in Chronic Kidney disease patients; trial did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in treated patients
May-05-15 04:05PMArdelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria PR Newswire
Apr-20-15 05:03PMARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Apr-20-15 09:46AMArdelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors at noodls
Apr-20-15 09:00AMArdelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors PR Newswire
Mar-13-15 01:04PMARDELYX, INC. Financials
Mar-13-15 09:05AMArdelyx to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference at noodls
Mar-13-15 09:00AMArdelyx to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference PR Newswire
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company's discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 agonists for inflammatory bowel disease, short bowel syndrome, and non-alcoholic steatohepatitis; and RDX013 for hyperkalemia. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaufmann MarkChief Financial OfficerMay 04Option Exercise0.549,0834,9059,679May 05 08:14 PM
Kaufmann MarkChief Financial OfficerMay 04Sale10.819,08398,232596May 05 08:14 PM
Kaufmann MarkChief Financial OfficerApr 06Option Exercise0.547,6814,1488,277Apr 08 05:31 PM
Kaufmann MarkChief Financial OfficerApr 06Sale12.807,68198,331596Apr 08 05:31 PM
Kaufmann MarkChief Financial OfficerMar 03Option Exercise0.546,0753,2816,671Mar 05 07:25 PM
TickerINPH [NASD]
CompanyInterphase Corp.
CountryUSA
IndustryComputer Peripherals
Market Cap8.33MEPS (ttm)-0.67
P/E-EPS this Y-76.90%
Forward P/E-EPS next Y-
PEG-EPS past 5Y3.20%
P/S0.60EPS next 5Y30.00%
P/B1.38EPS Q/Q-271.40%
Dividend-Sales Q/Q-32.60%
Insider Own0.60%Inst Own36.30%
Insider Trans-4.55%Inst Trans5.80%
Short Float0.04%EarningsMay 05/a
Analyst Recom-Target Price19.80
Avg Volume19.75K52W Range1.12 - 6.91
May-05-15 05:43PMInterphase Announces First Quarter 2015 Financial Results at noodls
May-05-15 04:56PMINTERPHASE CORP Files SEC form 8-K, Results of Operations and Financial Condition
May-05-15 04:40PMInterphase Announces First Quarter 2015 Financial Results Business Wire
May-05-15 07:07AMQ1 2015 Interphase Corp Earnings Release - After Market Close
Apr-30-15 08:13PM10-K for Interphase Corp. at Company Spotlight
Apr-28-15 07:23PMInterphase Schedules First Quarter 2015 Earnings Call GlobeNewswire
Apr-28-15 05:22PMInterphase Schedules First Quarter 2015 Earnings Call at noodls
Apr-16-15 04:10PMINTERPHASE CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
Apr-01-15 01:04PMINTERPHASE CORP Financials
Interphase Corporation, an information and communications technology company, provides embedded computing solutions, engineering design services, and contract manufacturing services in North America, the Pacific Rim, and Europe. The company's network connectivity products include OC-3/STM-1 asynchronous transfer mode network interface cards (NICs), Ethernet NICs, and T1/E1 communication controllers that primarily support SS7 signaling; interworking products comprise OC-3/STM-1 interworking modules, and broadband access gateway and media converters; and gigabit Ethernet (GigE) and 10 GigE packet processors. It also provides penveu, a handheld device primarily for use in the education market that adds interactivity to the installed base of projectors and large screen displays, making any flat surface, from pull down screens to HDTVs, an interactive display system. In addition, the company offers engineering design services, such as specifications gathering; program management; electrical, mechanical, and thermal design; wireless services design for cellular, Wi-Fi, Bluetooth, and other services; mechanical enclosure design; software design for drivers and applications; application software porting and integration; rapid prototyping; and manufacturability and testability design, product design verification testing, product certification, and production test development. Further, it offers electronics manufacturing services comprising supply chain management, custom branding and control, production assembly, system integration, testing and delivery, and inventory management and logistics services. The company sells its products and services to telecom equipment and server manufacturers, as well as to the electronics industry through its direct sales force, manufacturers' representatives, value-added distributors, tradeshows, and Web and social media tools. Interphase Corporation was founded in 1974 and is headquartered in Carrollton, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TIPTON THOMAS N JRCFO & VP of FinanceJan 13Sale2.279382,12929,343Jan 15 04:38 PM
Solomon YoramVP Corp. Strategy & Bus. Dev.Jan 13Sale2.277501,70317,544Jan 15 04:29 PM
MCCOMAS RANDALLVP of SalesJan 13Sale2.317171,6565,531Jan 15 04:21 PM
TickerSKUL [NASD]
CompanySkullcandy, Inc.
CountryUSA
IndustryElectronic Equipment
Market Cap249.68MEPS (ttm)0.26
P/E33.88EPS this Y345.50%
Forward P/E16.91EPS next Y31.57%
PEG2.26EPS past 5Y24.60%
P/S1.01EPS next 5Y15.00%
P/B1.63EPS Q/Q92.30%
Dividend-Sales Q/Q34.10%
Insider Own0.60%Inst Own61.90%
Insider Trans4.49%Inst Trans2.29%
Short Float5.42%EarningsMay 05/a
Analyst Recom2.20Target Price13.25
Avg Volume307.83K52W Range6.67 - 11.83
May-05-15 08:12PM10-K for Skullcandy, Inc. at Company Spotlight
May-05-15 06:31PMSkullcandy reports 1Q loss
May-05-15 05:28PMTuesday's After-Hours Movers: Borderfree Jumps Up 100%, Zulily Drops 18%
May-05-15 05:23PMSkullcandy Reports 18% First Quarter 2015 Net Sales Growth and Trims Operating Loss at noodls
May-05-15 04:30PMSkullcandy Inc Earnings Call scheduled for 4:30 pm ET today
May-05-15 04:29PMSKULLCANDY, INC. Files SEC form 8-K, Results of Operations and Financial Condition
May-05-15 04:14PM4:14 pm Skullcandy reports EPS in-line, beats on revs; guides Q2 EPS below consensus, revs below consensus; reaffirms FY15 EPS guidance, guides FY15 revs above consensus
May-05-15 04:01PMSkullcandy Reports 18% First Quarter 2015 Net Sales Growth and Trims Operating Loss GlobeNewswire
May-05-15 07:07AMQ1 2015 Skullcandy Inc Earnings Release - After Market Close
Skullcandy Inc. designs, markets, and distributes audio and gaming headphones, earbuds, speakers, and other accessories under the Skullcandy, Astro Gaming, and 2XL brands in the United States and internationally. It sells its products through specialty, consumer electronics, sporting goods, mobile phones, and big box retailers; and third party distributors, as well as through its skullcandy.com, skullcandy.tv, ca.skullcandy.com, eu.skullcandy.com, uk.skullcandy.com, 2xl.com, astrogaming.com, astrogaming.co.uk, and astrogaming.fr Websites. The company was founded in 2003 and is headquartered in Park City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Darling S HobyPRESIDENT AND CEONov 18Buy8.133,00024,386100,669Nov 19 05:32 PM
Hodell JasonCHIEF FINANCIAL OFFICERNov 18Buy8.124,30034,91661,469Nov 19 05:30 PM
TickerCLCD [NASD]
CompanyCoLucid Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap-EPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume-52W Range- - -
May-06-15 09:06AM9:06 am CoLucid Pharmaceuticals (Nasdaq: CLCD) priced its 5.5 mln share IPO at $10.00, in-line with revised terms vs. initial plans to offer 5.36 mln shares at $13.00-$15.00 per share
May-06-15 09:00AMCoLucid Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
CoLucid Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate, Lasmiditan, for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan, including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.
TickerCLUB [NASD]
CompanyTown Sports International Holdings Inc.
CountryUSA
IndustrySporting Activities
Market Cap127.67MEPS (ttm)-2.84
P/E-EPS this Y-668.00%
Forward P/E-EPS next Y80.00%
PEG-EPS past 5Y-62.60%
P/S0.28EPS next 5Y10.00%
P/B-EPS Q/Q-
Dividend12.33%Sales Q/Q-3.70%
Insider Own7.70%Inst Own70.50%
Insider Trans35.37%Inst Trans2.99%
Short Float3.22%EarningsMay 05/a
Analyst Recom2.50Target Price7.75
Avg Volume123.90K52W Range4.01 - 7.69
May-05-15 06:03PMTown Sports International Holdings, Inc. Announces First Quarter 2015 Financial Results at noodls
May-05-15 05:16PMTown Sports reports 1Q loss
May-05-15 04:02PMTOWN SPORTS INTERNATIONAL HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition
May-05-15 04:01PMTown Sports International Holdings, Inc. Announces First Quarter 2015 Financial Results Business Wire
May-05-15 07:07AMQ1 2015 Town Sports International Holdings Inc Earnings Release - After Market Close
Apr-28-15 04:52PMTown Sports International Holdings, Inc. Announces First Quarter 2015 Earnings Conference Call at noodls
Apr-28-15 04:01PMTown Sports International Holdings, Inc. Announces First Quarter 2015 Earnings Conference Call Business Wire
Mar-26-15 02:21PMHedge Funds Latest Moves: Diamondback Energy Inc (FANG), Walker & Dunlop, Inc. (WD), Town Sports International Holdings, Inc. (CLUB) at Insider Monkey
Mar-25-15 06:03AMTOWN SPORTS INTERNATIONAL HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modif
Town Sports International Holdings, Inc., together with its subsidiaries, owns and operates fitness clubs in the Northeast and Mid-Atlantic regions of the United States. It offers special purpose rooms for group fitness classes; and other exercise programs, as well as accommodates cardiovascular and strength-training equipment. The company also provides amenities, including swimming pools, racquet and basketball courts, babysitting services, and pro-shops; and fee-based programs services, which comprise personal training, small group training, children's programs, and other signature classes for adult members. It sells its memberships through direct sales, corporate and group sales, and call center, as well as through its online Website. As of December 31, 2014, the company operated 158 fitness clubs comprising 107 New York Sports Clubs, 30 Boston Sports Clubs, 13 Washington Sports Clubs, 5 Philadelphia Sports Clubs, 3 clubs located in Switzerland, and 1 BFX Studio. Town Sports International Holdings, Inc. was founded in 1973 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher DanielChief Executive OfficerApr 30Option Exercise3.544,20014,868179,297May 01 05:03 PM
Gallagher DanielChief Executive OfficerApr 30Sale6.204,20026,040175,097May 01 05:03 PM
Barron PaulChief Information OfficerApr 28Sale6.288075,06860,375Apr 29 04:18 PM
Ajmera NitinSVP - ControllerMar 12Sale6.175233,22722,942Mar 13 04:05 PM
Barron PaulChief Information OfficerMar 12Sale6.171,3808,51561,182Mar 13 04:06 PM
TickerNDLS [NASD]
CompanyNoodles & Company
CountryUSA
IndustryRestaurants
Market Cap498.33MEPS (ttm)0.37
P/E45.14EPS this Y54.20%
Forward P/E30.31EPS next Y22.17%
PEG2.29EPS past 5Y56.00%
P/S1.23EPS next 5Y19.75%
P/B3.55EPS Q/Q37.50%
Dividend-Sales Q/Q18.60%
Insider Own0.19%Inst Own80.00%
Insider Trans-98.18%Inst Trans1.62%
Short Float16.54%EarningsMay 05/a
Analyst Recom2.70Target Price22.83
Avg Volume775.80K52W Range17.05 - 35.82
May-06-15Reiterated RBC Capital Mkts Sector Perform $22 → $17
May-06-15Reiterated UBS Neutral $23 → $18
May-06-15 05:45PMStock Pops & Drops: NDLS, BUD, PLCE & WU
May-06-15 04:04PMThe 52-Week Low Club for Wednesday at 24/7 Wall St.
May-06-15 02:57PMUS stocks falling after weak jobs data; oil prices rise
May-06-15 01:06PMNoodles & Co.: When Earnings Disappoint From 'Top to Bottom' at Barrons.com
May-06-15 11:55AMNoodles stock continues slide with weak report, outlook
May-06-15 10:53AMCramer -- 'Disappointing' Earnings From Noodles, LendingClub Impressive at TheStreet
May-06-15 09:24AMNoodles & Co. (NDLS) Stock Continues to Tank Following Earnings Miss, Price Target Downgrade at TheStreet
May-06-15 09:22AMCramer's Mad Dash: Noodles disappoints
Noodles & Company develops and operates fast casual restaurants in the United States. It offers cooked-to-order dishes, including noodles and pasta, soups, salads, sandwiches, and appetizers. As of December 30, 2014, the company operated 439 restaurants comprising 386 company-owned and 53 franchised locations, across 32 states and the District of Columbia. Noodles & Company was founded in 1995 and is based in Broomfield, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reddy Kevin MichaelChief Executive OfficerFeb 27Buy18.405,00092,0005,000Mar 02 08:05 AM
Lockhart Kathryn RaeVice President & ControllerDec 02Option Exercise8.674,50039,0154,750Dec 02 04:48 PM
Lockhart Kathryn RaeVice President & ControllerDec 02Sale24.774,500111,465250Dec 02 04:48 PM
Boennighausen David JamesChief Financial OfficerNov 19Option Exercise8.6710,00086,70011,500Nov 21 04:01 PM
Boennighausen David JamesChief Financial OfficerNov 19Sale22.6410,000226,4001,500Nov 21 04:01 PM
TickerCEQP [NYSE]
CompanyCrestwood Equity Partners LP
CountryUSA
IndustryOil & Gas Pipelines
Market Cap1.05BEPS (ttm)0.30
P/E18.67EPS this Y400.00%
Forward P/E13.30EPS next Y14.09%
PEG1.70EPS past 5Y-24.30%
P/S0.27EPS next 5Y11.00%
P/B1.31EPS Q/Q122.20%
Dividend9.82%Sales Q/Q23.40%
Insider Own0.70%Inst Own68.80%
Insider Trans0.77%Inst Trans0.12%
Short Float1.28%EarningsMay 06/b
Analyst Recom2.70Target Price7.56
Avg Volume341.92K52W Range5.33 - 14.72
May-06-15 04:58PMCRESTWOOD EQUITY PARTNERS LP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
May-06-15 03:30PMRobbins Arroyo LLP: Acquisition of Crestwood Midstream Partners LP (CMLP) by Crestwood Equity Partners LP (CEQP) May Not Be in Shareholders' Best Interests PR Newswire
May-06-15 02:54PMREUTERS BUSINESS NEWS SCHEDULE AT 1830 GMT/2:30 PM ET
May-06-15 09:00AMCrestwood Equity Partners LP and Crestwood Midstream Partners LP Earnings Call scheduled for 9:00 am ET today
May-06-15 08:27AMCrestwood to buy unit in $3.5 bln deal to simplify structure Reuters
May-06-15 07:29AMCrestwood Equity Partners LP and Crestwood Midstream Partners LP Announce Merger Agreement at noodls
May-06-15 07:27AMCrestwood Equity Partners to buy affiliate Crestwood Midstream
May-06-15 07:07AMQ1 2015 Crestwood Equity Partners LP Earnings Release - Before Market Open
May-06-15 07:01AMCrestwood Equity Announces First Quarter 2015 Financial and Operating Results Business Wire
Crestwood Equity Partners LP provides midstream solutions to customers in the crude oil, natural gas liquids (NGLs), and natural gas sectors of the energy industry in the United States. It operates through three segments: Gathering and Processing; Storage and Transportation; and NGL and Crude Services. The Gathering and Processing segment engages in the gathering, processing, treating, compression, transportation, and sale of natural gas; and the delivery of natural gas liquids to producers in unconventional shale plays and tight-gas plays in West Virginia, Wyoming, Texas, Arkansas, New Mexico, and Louisiana. The Storage and Transportation segment offers natural gas storage and transportation services to producers, utilities, and other customers. This segment owns and operates natural gas storage facilities with approximately 79.3 billion cubic feet of natural gas storage capacity in New York and Pennsylvania. The NGL and Crude Services segment provides NGL and crude oil gathering, storage, marketing, and transportation services to producers, refiners, marketers, and other customers; and produces and sells salt products. Crestwood Equity GP LLC serves as the general partner of Crestwood Equity Partners LP. The company was formerly known as Inergy L.P. and changed its name to Crestwood Equity Partners LP in October 2013. The company is headquartered in Houston, Texas. Crestwood Equity Partners LP is a subsidiary of Crestwood Holdings LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GAUTREAUX WILLIAM CPresident, Liquids and CrudeDec 10Buy6.155,00030,7501,810,200Dec 10 04:34 PM
GAUTREAUX WILLIAM CPresident, Liquids and CrudeDec 09Buy6.355,00031,7501,805,200Dec 09 04:09 PM
SHERMAN JOHN JDirectorJul 31Sale15.093,60054,325577,853Aug 01 05:17 PM
SHERMAN JOHN JDirectorJul 30Sale15.1225,000378,035577,997Aug 01 05:17 PM
SHERMAN JOHN JDirectorJul 24Sale15.2525,000381,245581,997Jul 24 05:50 PM
TickerWLKP [NYSE]
CompanyWestlake Chemical Partners LP
CountryUSA
IndustryChemicals - Major Diversified
Market Cap577.46MEPS (ttm)0.78
P/E27.36EPS this Y-95.60%
Forward P/E15.39EPS next Y0.29%
PEG0.98EPS past 5Y0.00%
P/S0.33EPS next 5Y27.85%
P/B3.50EPS Q/Q-97.20%
Dividend5.15%Sales Q/Q-87.10%
Insider Own-Inst Own83.40%
Insider Trans-Inst Trans0.41%
Short Float0.09%EarningsMay 04/b
Analyst Recom2.70Target Price33.20
Avg Volume54.02K52W Range24.08 - 33.73
May-06-15 08:06AMWESTLAKE CHEMICAL PARTNERS LP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-06-15 02:16AM2:16 am Westlake Chemical Partners issues statement on proposed regulations relating to its qualifying income activities
May-05-15 10:35PMWestlake Chemical Partners LP Statement on Proposed Regulations Relating to its Qualifying Income Activities at noodls
May-05-15 09:25PMWestlake Chemical Partners LP Statement on Proposed Regulations Relating to its Qualifying Income Activities at noodls
May-05-15 09:18PMWestlake Chemical Partners LP Statement on Proposed Regulations Relating to its Qualifying Income Activities PR Newswire
May-04-15 07:45AMWESTLAKE CHEMICAL PARTNERS LP Files SEC form 8-K, Results of Operations and Financial Condition
May-04-15 07:23AMWestlake Chemical Partners LP Announces First Quarter Earnings at noodls
May-04-15 07:07AMQ1 2015 Westlake Chemical Partners LP Earnings Release - Before Market Open
May-04-15 06:30AMWestlake Chemical Partners posts 1Q profit
Westlake Chemical Partners LP focuses on producing and selling ethylene. It also sells ethylene co-products, including propylene, crude butadiene, pyrolysis gasoline, and hydrogen directly to third parties on either a spot or contract basis. The company was founded in 2014 and is headquartered in Houston, Texas. Westlake Chemical Partners GP LLC serves as the general partner of the company.
1 2 3 4 5 6 ... 10 ... 16 next